$0.23 EPS Expected for Abaxis, Inc. (ABAX)

December 27, 2017 – By Adrian Mccoy

Investors sentiment increased to 1.32 in 2017 Q3. Its up 0.20, from 1.12 in 2017Q2. It increased, as 11 investors sold Abaxis, Inc. shares while 36 reduced holdings. 18 funds opened positions while 44 raised stakes. 21.83 million shares or 0.11% less from 21.86 million shares in 2017Q2 were reported.
Spectrum Gp, Indiana-based fund reported 3 shares. 132,645 were reported by Ameriprise. Voya Mngmt Ltd Liability invested in 10,764 shares or 0% of the stock. Riverhead Mgmt Lc holds 0% in Abaxis, Inc. (NASDAQ:ABAX) or 2,153 shares. State Of Alaska Department Of Revenue has 4,487 shares for 0.01% of their portfolio. Royal Bank & Trust Of Canada reported 0.01% in Abaxis, Inc. (NASDAQ:ABAX). Deutsche National Bank & Trust Ag has invested 0% of its portfolio in Abaxis, Inc. (NASDAQ:ABAX). Credit Suisse Ag owns 27,460 shares or 0% of their US portfolio. Bancshares Of Mellon accumulated 312,478 shares. Stifel Financial has 0% invested in Abaxis, Inc. (NASDAQ:ABAX) for 26,512 shares. Moreover, Nationwide Fund Advsr has 0.02% invested in Abaxis, Inc. (NASDAQ:ABAX). Wesbanco Commercial Bank invested 0.01% in Abaxis, Inc. (NASDAQ:ABAX). Citigroup Inc holds 13,074 shares or 0% of its portfolio. Spark Invest Mgmt Ltd reported 41,300 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 598 shares or 0% of the stock.

Analysts expect Abaxis, Inc. (NASDAQ:ABAX) to report $0.23 EPS on January, 25.They anticipate $0.07 EPS change or 23.33 % from last quarter’s $0.3 EPS. ABAX’s profit would be $5.22M giving it 53.93 P/E if the $0.23 EPS is correct. After having $0.29 EPS previously, Abaxis, Inc.’s analysts see -20.69 % EPS growth. The stock increased 0.02% or $0.01 during the last trading session, reaching $49.62. About 143,141 shares traded or 23.29% up from the average. Abaxis, Inc. (NASDAQ:ABAX) has risen 7.18% since December 27, 2016 and is uptrending. It has underperformed by 9.52% the S&P500.

Abaxis, Inc. (NASDAQ:ABAX) Ratings Coverage

Among 9 analysts covering Abaxis (NASDAQ:ABAX), 0 have Buy rating, 4 Sell and 5 Hold. Therefore 0 are positive. Abaxis had 22 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was downgraded by Bank of America to “Underperform” on Wednesday, October 21. Northcoast downgraded Abaxis, Inc. (NASDAQ:ABAX) on Wednesday, November 30 to “Neutral” rating. Stifel Nicolaus maintained the shares of ABAX in report on Friday, January 27 with “Hold” rating. The firm has “Underperform” rating by Bank of America given on Wednesday, October 25. The firm has “Neutral” rating by CL King given on Friday, April 1. The firm has “Underperform” rating by Credit Suisse given on Thursday, February 4. The rating was maintained by Canaccord Genuity on Friday, October 27 with “Hold”. Bank of America maintained it with “Underperform” rating and $42 target in Wednesday, August 23 report. Canaccord Genuity maintained Abaxis, Inc. (NASDAQ:ABAX) rating on Thursday, July 23. Canaccord Genuity has “Buy” rating and $62 target. As per Monday, October 23, the company rating was maintained by Stifel Nicolaus.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. The company has market cap of $1.13 billion. It operates in two divisions, Medical Market and Veterinary Market. It has a 41.7 P/E ratio. The firm offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.

More news for Abaxis, Inc. (NASDAQ:ABAX) were recently published by: Prnewswire.com, which released: “Abaxis, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference” on November 01, 2017. Streetinsider.com‘s article titled: “Form 8-K ABAXIS INC For: Nov 29” and published on November 30, 2017 is yet another important article.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.